Q2 2026 SAB Biotherapeutics Inc Earnings Call Transcript
Key Points
- SAB Biotherapeutics Inc (SABS) is on track to complete enrollment in its registrational Phase 2b SAFEGUARD trial in Q4 2026, with top-line data expected in the second half of 2027.
- The company has over 60 active clinical sites, driving steady growth in screening and randomization for the SAFEGUARD study.
- Breakthrough T1D awarded a grant to support the PRIZE-HAPG study, providing external validation and co-funding for the company's approach in a broader patient population.
- The recent FDA approval of Tzield for Stage 3 type 1 diabetes validates the regulatory path for C-peptide as an accelerated approval endpoint, potentially benefiting SAB142's development.
- SAB Biotherapeutics Inc (SABS) ended Q2 2026 with $208 million in cash, providing an operational runway through 2028 to support key clinical milestones.
- The company's SAB142 offers potential competitive advantages over Tzield, including a shorter two-day dosing regimen and low immunogenicity, which may support safe redosing.
- Construction of a second farm facility in South Dakota is underway to establish a redundant herd, reducing operational risks and supporting long-term commercial supply.
- Net loss widened to $22.5 million in Q2 2026, up from $10.1 million in the same period of 2025, reflecting increased R&D and G&A expenses.
- R&D expenses more than doubled year-over-year to $16.2 million, driven by higher clinical trial costs and headcount, which may pressure future cash flows.
- G&A expenses increased significantly to $7.2 million from $2.7 million, partly due to higher stock-based compensation, indicating rising operational costs.
- The PRIZE-HAPG study is expected to start enrolling in the second half of 2026, with top-line results not expected until Q1 2029, representing a long timeline for potential label expansion.
- The company did not disclose screening failure rates or other detailed enrollment metrics, limiting transparency on trial execution risks.
- The recent FDA approval of Tzield could increase competitive pressure, as it may set a higher bar for SAB142's differentiation and commercial adoption.
- The company's reliance on a limited number of sites for the PRIZE study (seven sites) may pose enrollment challenges, despite anticipated patient demand.
(Operator Instructions)
Good morning and welcome to SAB BIOS conference call to discuss second quarter 2026 financial results and business updates.
(Operator Instructions)
I'll now turn the call over to Samuel Reich, Chief Executive Officer of SAB Bio.
Thank you, operator. Good morning and thank you to everyone joining us for our second quarter 2025 earnings call.
I'm joined today by Lucy To, our Chief Financial Officer, who will review the second quarter financial updates. I'm also joined by Eddie Sullivan, our Co-Founder and President, and Alexandra Kropotova, our Chief Medical Officer.
We're pleased to have you with us today to share the progress we've made in the second quarter.
We remain focused on execution, delivering meaningful progress in our safeguard study, and advancing key clinical and operational priorities.
For those who may be new to the SAB Bio story, we are a clinical-stage biopharmaceutical company focused on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
